IACC Launches Trailblazing Marketplace Advisory Council (MAC)
Landmark Collaboration Brings Together Online Marketplaces, Payment, and Brand Leaders to Combat Counterfeiting
SAN DIEGO, May 13, 2025 /PRNewswire/ -- In an unprecedented show of unity, some of the world's most influential companies, spanning e-commerce, payments, and global brands, have come together under the leadership of the International AntiCounterfeiting Coalition (IACC) to confront one of the most pressing challenges of the digital age: ensuring a safe, trusted, and counterfeit-free online marketplace. Today in San Diego, the IACC proudly launched its Marketplace Advisory Council (MAC) - a groundbreaking forum that sets a new standard for cross-industry collaboration in the fight against fakes.
MAC unites a distinguished group of participants, including Alibaba Group, Amazon, DHGate, eBay, Meta, Mercado Libre, Shopee, and Temu, alongside payment partners Mastercard, PayPal, and Visa. Global brands participating in the initiative include Calvin Klein, Ford, Motion Picture Association, Adidas, Merck, Chanel, Colgate-Palmolive, Tenneco, Disney, ESA, Estée Lauder, Apple, John Deere, Burberry, Johnson & Johnson, Levi Strauss & Co., Nike, the Recording Industry Association of America (RIAA), and Zimmermann.
Drawing on its unmatched track record of delivering results through cross-industry partnership, the IACC is elevating its collaborative work through MAC. This initiative marks a pivotal step forward, offering participants a unique opportunity to work together, share insights, and forge stronger partnerships that support the growth and integrity of the online marketplace.
The formation of MAC reflects the IACC's long-standing commitment to proactive, solution-oriented engagement. By providing a forum where platforms, payment providers, and brands can exchange perspectives, address shared challenges, and explore new strategies together, the IACC reinforces that collaboration remains the most powerful tool in combating counterfeiting and IP crime.
"IACC has always believed that collaboration is the key to meaningful progress," said Bob Barchiesi, President of the IACC. "With the creation of MAC, we are forging a new path - bringing together a diverse group of pioneers to shape the future of brand protection through dialogue, trust, and shared commitment, and laying the foundation for lasting impact across the global marketplace."
About the IACCThe IACC (www.iacc.org) is a leading not-for-profit organization dedicated to combating intellectual property theft and representing the interests of global brands across all sectors. Known for pioneering cross-industry agreements, the IACC leads initiatives such as IACC MarketSafe® and RogueBlock®, aimed at curbing the online sale of counterfeit and pirated goods.
View original content to download multimedia:https://www.prnewswire.com/news-releases/iacc-launches-trailblazing-marketplace-advisory-council-mac-302454594.html
SOURCE International AntiCounterfeiting Coalition
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Paramount layoffs: TV and movie giant cuts 3.5% of U.S. workforce ahead of merger with Skydance Media, citing uncertain economy
Paramount Global is cutting 3.5% of its U.S. workforce as customers switch away from traditional pay-TV bundles in today's shifting media landscape and uncertain economy. RIP to the almost future of computing: Apple just turned the iPad into a Mac Why Third Amendment memes are suddenly taking over social media China is arming its space station with 'guard dogs.' They have good reason for it The latest round of layoffs comes as the media giant prepares to merge with movie studio Skydance Media. Paramount Global's parent company, National Amusements, and Skydance Media agreed to merge last July, but are still waiting for regulatory approval. Paramount owns Paramount Pictures movie and television studios, the Paramount+ streaming service, MTV, Nickelodeon, BET, Comedy Central, and the CBS television network including CBS News. Shares in Paramount Global (PARA) were trading up about 1% in late morning trading at the time of this writing. On Tuesday, Paramount's co-CEOs George Cheeks, Chris McCarthy, and Brian Robbins notified staff of layoffs in a memo, which said 90% of those impacted would be notified on Tuesday, according to CNBC. Last August, Paramount began the process of reducing its U.S.-based workforce by 15% after laying out a cost-cutting plan. The layoffs are just the latest to hit the beleaguered media industry, which has also seen staff cuts at Disney and Warner Bros. Discovery, to name a few. In Paramount Global's latest round of earnings, for the first quarter of 2025, ending March 31, 2025, the media company reported earnings per share (EPS) of $0.29, missing analysts estimates; and quarterly revenue of $7.19 billion, slightly beating analyst expectations of $7.14 billion. The company forecast that earnings would grow by 54.67% next year, from $2.25 to $3.48 per share. The company is slated to report Q2 earnings in early August. This post originally appeared at to get the Fast Company newsletter: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Tom's Guide
3 hours ago
- Tom's Guide
I review MacBooks for a living: 3 macOS Tahoe 26 features I'm most excited about
I just got back from covering WWDC 2025 in Cupertino, and after cooking in the sun for a few hours to catch the keynote I have to say: I'm impressed by what the company is doing with macOS. That's not a sentence I type often, but the colorful visionOS-inspired makeover Apple is delivering with Tahoe has me charmed. On top of that, there are a few new features that promise to make even the best MacBooks a bit more capable. Of course, I review Macs for a living here at Tom's Guide so I might be a little biased when it comes to getting excited about operating systems. But I also reviewed the last few iterations of macOS, and I have to tell you: Tahoe is (for my money) the most promising update Apple's debuted in years. Let me show you what I mean by highlighting a few of the most interesting new features I've seen here at Apple HQ. Apple Intelligence made its Mac debut in macOS Sequoia, and it's fine. Some people find the AI-powered Writing Tools useful, and playing around with Image Playground is fun a few times. But like most of Sequoia's AI-powered features, it's easy to forget about. With macOS Tahoe 26, Apple promises to make a slew of updates to Apple Intelligence features throughout your Mac. So not only should the image and text generation tools get better, but your Reminders will get more intelligent—or at least, more dynamic in what and how they remind you. But most exciting to me is the Apple Intelligence-fueled overhaul coming to Spotlight Search. The contextual search tool will gain support for a host of new actions and services, plus it will allow for more natural language in queries. So you can type something like "Send", for example, and you will see a list of search results drop down with uses of the word across your email, Notes and more—and the top option will be a shortcut to send a text via the Shortcuts app, so you can just hit Return and start typing the message right in Spotlight Search. Get instant access to breaking news, the hottest reviews, great deals and helpful tips. If this works as advertised I expect Spotlight Search is going to become sort of like the Start button in Windows 11: the first stop and one-stop shop for power users looking to get things done. I just think it's so cool that Macs are going to get real-time translation with macOS Tahoe. I know I probably won't have much cause to make use of translated Messages or real-time translated captions in FaceTime calls, but the fact that it'll soon be so easy to chat with folks around the world on your MacBook without having to speak the same language feels mind-blowing. Plus, since Apple is opening up a large swathe of its Apple Intelligence tech to third-party developers, I expect we'll also see a slew of Mac apps getting real-time translation features in the next few years. I'm not always psyched about new AI features in tech, but real-time translation seems like an unalloyed good — and one of the best new features of macOS Tahoe 26. Look, it's never going to replace Steam, but I do think it's exciting that Apple is finally shipping a dedicated Games app for macOS Tahoe. By all accounts this new app aims to be your one-stop shop for gaming on your Mac, and it will feature a special in-game overlay you can summon during gameplay to do things like message friends. Windows 11 has a very similar overlay, and I don't love how it gets in the way when PC gaming in Steam's Big Picture mode. Hopefully Apple's version doesn't create similar headaches, but we'll have to wait until macOS Tahoe 26 ships in September to find out. Even if the new Games app isn't amazing at launch, I hope it's evidence that Apple is investing more effort and money in supporting Mac game devs and nurturing the Mac gaming landscape.
Yahoo
4 hours ago
- Yahoo
Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD
NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on continued momentum with United States Food and Drug Administration (FDA) regarding both accelerated approval pathway for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic chronic heart failure with reduced ejection fraction (HFrEF) and inflammation, and label extension for Ryoncil® (remestemcel-L-rknd) in adults with steroid refractory acute graft versus host disease (SR-aGvHD). In the first week of June, Mesoblast held a Type B meeting with FDA under its Regenerative Medicines Advanced Therapy (RMAT) designation for REVASCOR to discuss components of a potential filing for a Biologics License Application (BLA). There was general alignment on items regarding chemistry, manufacturing & controls (CMC), potency assays for commercial product release, and proposed design and primary endpoint for the confirmatory trial post-approval. The Company will await the final minutes from FDA in order to provide detailed feedback and timelines for potential filing. In early July, Mesoblast has an upcoming meeting with FDA to discuss a pivotal trial of Ryoncil® in adults with SR-aGvHD. This trial will be conducted with the NIH-funded Bone Marrow Transplant Clinical Trials Network (BMT-CTN), the objective being to extend the product's label from children to adults with SR-aGvHD. Ryoncil® is the first and only mesenchymal stromal cell product approved by the FDA for any indication. Ryoncil® became commercially available for purchase in the United States on March 28, 2025, within one quarter of receiving FDA approval to treat children with SR-aGvHD. More than 20 transplant centers will have been onboarded by the end of the quarter, exceeding the company's expectations at product launch. Mesoblast has continued to expand coverage for Ryoncil® to over 220 million US lives insured by commercial and government payers. To date, 37 of the 51 States provide fee-for-service Medicaid coverage for Ryoncil® through Orphan Drug Lists or medical exception / prior authorization (PA) process. The remainder will come online July 1, 2025, with mandatory coverage for all 24 million lives. 'We are very pleased with the momentum of interactions with FDA on both our cardiac and GvHD programs,' said Mesoblast Chief Executive Dr. Silviu Itescu. 'We are also encouraged by the strength of the of the Ryoncil® commercial launch, the rate of hospital onboarding, physician adoption, and payor coverage exceeding our expectations in the ten weeks since commercial launch. We will be providing an update on sales of Ryoncil® in our quarterly activities report at the end of next month.' About Mesoblast Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company's proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process. Mesoblast's RYONCIL® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. RYONCIL is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China. About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications are expected to provide commercial protection extending through to at least 2041 in major markets. About Mesoblast manufacturing: The Company's proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see LinkedIn: Mesoblast Limited and X: @Mesoblast Forward-Looking StatementsThis press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast's preclinical and clinical studies, and Mesoblast's research and development programs; Mesoblast's ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast's ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast's RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast's product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast's ability to enter into and maintain established strategic collaborations; Mesoblast's ability to establish and maintain intellectual property on its product candidates and Mesoblast's ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast's expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast's financial performance; developments relating to Mesoblast's competitors and industry; and the pricing and reimbursement of Mesoblast's product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast's actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise. Release authorized by the Chief Executive. For more information, please contact:Paul Hughes T: +61 3 9639 6036 Allison Worldwide Emma Neal T: +1 603 545 4843 E: BlueDot Media Steve Dabkowski T: +61 419 880 486 E: steve@
